Definitive Contract 75A50119C00059
Award Date
9/5/19
Potential Completion Date
12/31/20
Potential Value
$14M
Awardee
Ridgeback Biotherapeutics LP
Ultimate Awardee
Not listed
NAICS Category
541713 - Research and Development in Nanotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Coconut Grove, FL 33133, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a sole-source contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Ridgeback Biotherapeutics LP for the development and manufacturing of the monoclonal antibody treatment mAb114 for Ebola virus disease (EVD). The contract has a ceiling value of $159,990,035.88 and a period of performance through July 31, 2023. It was awarded on March 19, 2020 as a cost-plus-fixed-fee definitive contract. The...
This $2,306,148 federal contract was awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Battelle Memorial Institute to support an efficacy study of a monoclonal antibody (MAb) therapeutic against the Ebola virus (EBOV) lethal challenge in rhesus macaques. The contract is a Delivery Order issued under Battelle's BARDA Biological Animal Model Development 2017-2022 Indefinite Delivery/Indefinite Quantity (IDIQ)...
This is a $906,651,397.58 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Mapp Biopharmaceutical, Inc., a for-profit biotechnology company based in San Diego, California. The contract is for the procurement of therapeutics for Ebola, Sudan, and Marburg viruses, with a period of performance running through September 29, 2032. This contract has no set-aside designation. Mapp Biopharmaceutical is...
This is a $62,511,942.00 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California. The contract is for the development of an anti-Sudan ebolavirus medical countermeasure, a critical public health and national security priority. Mapp Biopharmaceutical has a strong...
This is a federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency within the U.S. Department of Health and Human Services, to Profectus Biosciences, Inc., a small business contractor. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a ceiling value of $7,524,330.27 and a period of performance through November 30, 2016. The contract is for the GMP (Good Manufacturing Practice) manufacture of the...
This $38,243,034.02 cost-plus-fixed-fee contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract, which has no set-aside designation, is for the development of medical countermeasures through planned clinical trials and outbreak preparedness. This contract builds on...
This is a cost-plus-fixed-fee definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The contract, which has a potential value of $7,486,450.79, is for an expanded access protocol for the drug ZMapp to treat viral hemorrhagic fevers like Ebola, Marburg, and Lassa. Mapp Biopharmaceutical is a prime contractor for ASPR, having...
This is a $762,812,695.00 firm fixed price contract awarded by the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to Emergent Product Development Gaithersburg Inc., a for-profit manufacturer of medical countermeasures. The contract is for the development of medical countermeasures that can be deployed in the event of a filovirus outbreak, which is a crucial component of the U.S. government's outbreak response plan. The...
<p>This is a $81,976,383.00 definitive, cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian federal agency, to Public Health Vaccines LLC, a self-certified small disadvantaged business, for the advanced research and development of an RVSV-MARV vaccine. The contract has an ultimate completion date of August 31, 2027 and was awarded on February 1, 2019. The contract does not have a set-aside designation.</p>
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...